CD16 anticorps

N° du produit ABIN2749016

Détail du produit anti-CD16 anticorps

Antigène: CD16

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp CD16 est non-conjugé

Application: Flow Cytometry (FACS), Immunoprecipitation (IP), Western Blotting (WB), Functional Studies (Func)

Specificité: The antibody MEM-154 reacts with an extracellular epitope on CD16 antigen that is residing in proximity to FG loop (probably BC or C'E loop). CD16 is a low affinity receptor for aggregated IgG (FcgammaRIII antigen). The antibody MEM-154 reacts with CD16+ granulocytes, and it can be used for mapping CD16-158V/F polymorphism on NK cells, as it requires presence of V at amino acid 158.

Réactivité croisée (Details): Human

Purification: Purified by protein-A affinity chromatography.

Pureté: > 95 % (by SDS-PAGE)

niveau d'endotoxine: Endotoxin level is less than 0.01 EU/µg of the protein, as determined by the LAL test.

Immunogène: Human granulocytes

Clone: MEM-154

Isotype: IgG1

Information d'application

Indications d'application: Functional application: The antibody MEM-154 blocks binding of human IgG to FcγRIII.
Flow cytometry: Recommended dilution: 5-10 μg/mL, positive control: PBL (peripheral blood lymphocytes). The antibody MEM-154 does not react with CD16a present on NK cells in many subjects.
Western blotting: Non-reducing conditions.

Restrictions: For Research Use only

Stockage

Concentration: 1 mg/mL

Buffer: Phosphate buffered saline (PBS), pH 7.4

Agent conservateur: Azide free

Stock: 4 °C

Stockage commentaire: Store at 2-8°C. Do not freeze.

Références pour anticorps anti-CD16 (ABIN2749016)

Gasdaska, Sherwood, Regan, Dickey: "An afucosylated anti-CD20 monoclonal antibody with greater antibody-dependent cellular cytotoxicity and B-cell depletion and lower complement-dependent cytotoxicity than rituximab." dans: Molecular immunology, Vol. 50, Issue 3, pp. 134-41, (2012) (PubMed).

Koene, Kleijer, Algra, Roos, von dem Borne, de Haas: "Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype." dans: Blood, Vol. 90, Issue 3, pp. 1109-14, (1997) (PubMed).

de Haas, Koene, Kleijer, de Vries, Simsek, van Tol, Roos, von dem Borne: "A triallelic Fc gamma receptor type IIIA polymorphism influences the binding of human IgG by NK cell Fc gamma RIIIa." dans: Journal of immunology (Baltimore, Md. : 1950), Vol. 156, Issue 8, pp. 2948-55, (1996) (PubMed).

Tamm, Schmidt: "The binding epitopes of human CD16 (Fc gamma RIII) monoclonal antibodies. Implications for ligand binding." dans: Journal of immunology (Baltimore, Md. : 1950), Vol. 157, Issue 4, pp. 1576-81, (1996) (PubMed).

Détails sur CD16

Antigène: CD16

Autre désignation: CD16 (CD16 Produits)

Synonymes: anticorps Fcgr3, anticorps Fcgr3a, anticorps CD16, anticorps FCGR3, anticorps FCGR3@, anticorps CD16b, anticorps FCG3, anticorps FCR-10, anticorps FCRIII, anticorps FCRIIIb, anticorps FcRIII, anticorps Fc fragment of IgG, low affinity IIa, receptor, anticorps Fc fragment of IgG, low affinity IIIa, receptor (CD16a), anticorps Fc fragment of IgG receptor IIIb, anticorps Fc fragment of IgG receptor IIIa, anticorps Fc receptor, IgG, low affinity III, anticorps Fc-gamma RIII, anticorps Fcgr2a, anticorps FCGR3A, anticorps FCGR3B, anticorps Fcgr3, anticorps FCGR3

Sujet: CD16 (FcgammaRIII) is a 50-65 kDa glycoprotein serving as a low affinity IgG receptor. Human FcgammaRIII is expressed in two forms –, FcgammaRIII-A and -B. FcgammaRIII-A is a transmembrane protein of monocytes, macrophages, NK cells and a subset of T cells. It is associated with FcepsilonRI-gamma subunit and is responsible for antibody-dependent NK cell cytotoxicity. Mast cell FcgammaRIII-A is associated, moreover, with FcepsilonRI-beta subunit. Besides IgG, FcgammaRIII-A can be triggered also by oligomeric IgE. FcgammaRIII-B is a GPI-linked monomeric receptor expressed on neutrophils and is involved in their activation and induction of a proadhesive phenotype.,FcgammaRIII, IGFR3, FCRIII

Pathways: Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process